WO2010137689A1 - 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 - Google Patents
注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 Download PDFInfo
- Publication number
- WO2010137689A1 WO2010137689A1 PCT/JP2010/059085 JP2010059085W WO2010137689A1 WO 2010137689 A1 WO2010137689 A1 WO 2010137689A1 JP 2010059085 W JP2010059085 W JP 2010059085W WO 2010137689 A1 WO2010137689 A1 WO 2010137689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- lower alkyl
- group
- aryl
- different
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel pharmaceutical use of a BEC1 potassium channel inhibitor as a pharmaceutical composition for the prevention and / or treatment of attention deficit / hyperactivity disorder.
- Attention deficit / hyperactivity disorder means inattention (not able to concentrate on things, many things left behind), hyperactivity (can't stay calm and still), Developmental disorder with three central symptoms of impulsivity (perceived behavior abruptly, unable to wait in turn) (American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision: DSM-IV-TR. American Psychiatric Association, Washington, D. C., 2000).
- hyperactivity is often reduced around 11 years old and impulsiveness is often reduced around 13 years old, but inattentive symptoms often persist for a long time until adulthood. According to a recent survey, about 70% in adolescence (Barkley, R.
- attention deficit / hyperactivity disorder is one of the most common mental illnesses in children. Approximately 4 million children in the United States have been diagnosed with attention deficit / hyperactivity disorder. Prevalence among school-age children is said to be 3-7% (American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision: DSM-IV-TR. American Psychiatric Association, Washington, D. C., 2000). Children with this disease exhibit dysfunction in a variety of situations, including at home, school, and relationships with friends. If not treated, adverse effects will occur over a long period from childhood to adulthood.
- NIMH National Institutes for Mental Health
- ⁇ ⁇ Drug therapy and psychosocial therapy are mainly used to treat attention deficit / hyperactivity disorder.
- Drug therapy is extremely effective in controlling symptoms, and realistic changes appear in the person's behavior, thinking, learning ability, and interpersonal relationships.
- the central nervous system drug methylphenidate is the first-line drug. Symptoms in which methylphenidate is effective include hyperactivity, difficulty in concentrating attention, impulsivity, and anxiety. Methylphenidate is said to relieve symptoms in 70 to 80% of children with attention deficit / hyperactivity disorder (Non-patent Document 1), but because of its central stimulant, it can be abused There is sex. For this reason, methylphenidate is classified as a controlled substance in Schedule II, which indicates drugs that are likely to be abused in the United States. In addition, it is a drug of schedule II in the Convention on Psychotropic Substances ⁇ , and its use as a first-type psychotropic drug is severely restricted in Japan.
- Potassium channels are proteins that exist in the plasma membrane of cells and selectively pass potassium ions, and are thought to play an important role in cell membrane potential control.
- nerve / muscle cells contribute to the central / peripheral nerve transmission mechanism, cardiac pacemaking, muscle contraction, etc. by adjusting the frequency and persistence of action potentials. It has also been shown to be involved in hormone secretion, cell volume regulation, cell proliferation, and the like.
- the voltage-gated potassium channel has a characteristic of opening when the membrane potential is depolarized.
- potassium ions are present in a non-equilibrium state at about 5 ⁇ m extracellular and about 150 ⁇ m intracellular.
- a voltage-gated potassium channel is opened by depolarization, potassium ions flow out from the cell to the outside of the cell, and as a result, the membrane potential is restored (repolarization). Therefore, a decrease in the excitability of nerve and muscle cells is induced with the opening of the voltage-gated channel (Hille, B. (ed) Ionic Channels of Excited Membranes, Sinauer Associates, Sunderland, 1992).
- BEC1 or BEC1 potassium channel The potassium channel described in SEQ ID NO: 2 of Example 1 of Patent Document 1 (hereinafter referred to as BEC1 or BEC1 potassium channel) is a voltage-dependent potassium channel showing an expression distribution limited to the brain. Its expression is particularly prominent in the hippocampus and cerebral cortex. The hippocampus and cerebral cortex are areas that are strongly associated with memory and learning (Levitan, I. B. and Kaczmarek, L. K. The neuron: Cell and Molecular Biology, Oxford University Press, New York , NY, 1991).
- BEC1 potassium channel may be involved in memory and learning.
- BEC1 channels are highly expressed in the hippocampus and cerebral cortex, it is clear that the mice have reduced learning ability in the Morris water maze learning test and the passive avoidance learning test. (Patent Document 2). This suggests that inhibitors of the BEC1 potassium channel may enhance memory and learning and are extremely promising as therapeutic agents for dementia.
- BEC1 channel inhibitors consisting of 2, 4, 6-triamino-1, 3, 5-triazine derivatives describe the study results on learning disorders, and these BEC1 channel inhibitors are therapeutic agents for dementia drugs. It is described as being useful.
- the knowledge which suggests that the said BEC1 channel inhibitor shows the utility with respect to attention deficit / hyperactivity disorder has not been reported so far.
- An object of the present invention is to provide a therapeutic agent for attention deficit / hyperactivity disorder having a novel mechanism of action different from conventional central stimulants.
- the present inventors have conducted research based on an original idea to achieve the above-mentioned problems, and found that a BEC1 potassium channel inhibitor exhibits a remarkable therapeutic effect on attention deficit / hyperactivity disorder and completed the present invention. I let you.
- the object of the present invention is to prevent and / or treat attention deficit / hyperactivity disorder comprising 1) a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof, and 2) a pharmaceutically acceptable carrier. It is to provide a pharmaceutical composition for use. Another object of the present invention is to provide a prophylactic and / or therapeutic agent for attention deficit / hyperactivity disorder containing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient. It is a further object of the present invention to provide a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof for the prevention and / or treatment of attention deficit / hyperactivity disorder.
- a further object of the present invention is to provide the use of a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating attention deficit / hyperactivity disorder. It is a further object of the present invention to provide a method for treating attention deficit / hyperactivity disorder comprising administering to a patient an effective amount of a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof. A further object of the present invention is to treat attention deficit / hyperactivity disorder comprising mixing a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. It is providing the manufacturing method of the pharmaceutical composition for.
- the present invention relates to a drug for the prevention and / or treatment of attention deficit / hyperactivity disorder comprising 1) a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof and 2) a pharmaceutically acceptable carrier.
- a drug for the prevention and / or treatment of attention deficit / hyperactivity disorder comprising 1) a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof and 2) a pharmaceutically acceptable carrier.
- the present invention is particularly useful as a pharmaceutical composition for preventing and / or treating attention deficit / hyperactivity disorder carelessness, impulsivity, hyperactivity, and the like.
- the “hydrocarbon group” is a linear or branched hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, or a cyclic hydrocarbon group having 3 to 15 carbon atoms.
- the linear or branched hydrocarbon group includes “alkyl”, “alkenyl”, “alkynyl” and the like. Specific examples of “alkyl” include methyl, ethyl, isopropyl, hexyl, decyl, tetradecyl, pentadecyl and the like.
- Alkenyl is a hydrocarbon group having at least one double bond.
- alkenyl examples include vinyl, propenyl, allyl, isopropenyl, hexenyl and the like.
- Alkynyl is a hydrocarbon group having at least one triple bond, and specific examples of “alkynyl” include ethynyl, propynyl, butynyl and the like.
- Examples of the cyclic hydrocarbon ring group include “cycloalkyl”, “cycloalkenyl”, “aryl” and the like.
- “Lower alkyl” means linear or branched alkyl having 1 to 6 carbon atoms (hereinafter abbreviated as C 1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl group and the like.
- C 1-6 is linear or branched alkyl having 1 to 6 carbon atoms (hereinafter abbreviated as C 1-6 ), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl group and the like.
- Another embodiment is C 1-4 alkyl
- yet another embodiment is methyl, ethyl, propyl, isopropylbuty
- C 1-10 alkylene means linear or branched C 1-10 alkylene such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, decamethylene, Propylene, methylmethylene, ethylethylene, 1,2-dimethylethylene, 1,1,2,2-tetramethylethylene and the like.
- Halogen means F, Cl, Br, I.
- Cycloalkyl is a C 3-15 saturated hydrocarbon ring group which may have a bridge. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl group and the like. Another embodiment is a C 3-15 saturated hydrocarbon ring group, yet another embodiment is C 3-8 cycloalkyl, and yet another embodiment is C 3-6 cycloalkyl.
- cycloalkenyl is C 4-15 cycloalkenyl, which may have a bridge, and includes a cyclic group condensed with a benzene ring at a double bond site.
- C 5-10 cycloalkenyl is C 4-15 cycloalkenyl, which may have a bridge, and includes a cyclic group condensed with a benzene ring at a double bond site.
- Aryl is a C 6-14 monocyclic to tricyclic aromatic hydrocarbon ring group such as phenyl and naphthyl, and in another embodiment, phenyl.
- Heterocycle group refers to a 3 to 15 membered, alternatively 5 to 10 membered mono to tricyclic heterocycle containing from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen Groups, including saturated rings, aromatic rings, and partially hydrogenated ring groups thereof. Ring atoms such as sulfur or nitrogen may be oxidized to form oxides or dioxides.
- Another embodiment is a 5- to 10-membered monocyclic to bicyclic heterocyclic group, and yet another embodiment is a 5- to 6-membered monocyclic heterocyclic group, In an embodiment, it is a 5-6 membered monocyclic heteroaryl.
- hydrocarbon group and “heterocyclic group” in “optionally substituted hydrocarbon group” and “optionally substituted heterocyclic group” are selected from the following group A: It is a group. Group A —OH, —NH 2, —NH (lower alkyl), —N (lower alkyl) 2 , —CN, —COOH, NO 2 , lower alkyl, lower alkyl-O—, halogen, cycloalkyl, aryl, and hetero Ring group.
- the cycloalkyl, aryl, and heterocyclic groups described in Group A above may be substituted with a substituent selected from Group B below.
- Group B OH, —NH 2 , —NH (lower alkyl), —N (lower alkyl) 2 , —CN, —COOH, NO 2 , lower alkyl, lower alkyl-O—, halogen, cycloalkyl, aryl, and hetero Ring group.
- BEC1 or “BEC1 potassium channel” means the full-length protein shown in SEQ ID NO: 2 in US Pat. No. 6,326,168 or US Pat. No. 7,375,222.
- BEC1 potassium channel inhibitor means a substance that inhibits BEC1 potassium channel.
- the IC 50 value is 10 ⁇ M or less, and in another embodiment, 1 ⁇ M or less, In another embodiment, the substance is 0.5 ⁇ M or less.
- the BEC1 potassium channel inhibitory activity can also be confirmed by subjecting the test compound to a typical screening method such as the method described in US Pat. No. 6,326,168 or US Pat. No. 7,375,222.
- a BEC1 potassium channel inhibitor has the formula (I) (The symbols in the formula are as follows.
- R 1 and R 2 are the same or different: (i) H, (ii) OH, (iii) alkyl-O-, (iv) aryl-CO-, (v) H 2 N, (vi) (OH optionally substituted alkyl) -NH, (vii) (alkyl) 2 N, (viii) optionally substituted hydrocarbon group, or, (ix) an optionally substituted heterocyclic group;
- R 3 , R 4 , R 5 and R 6 are the same or different and are selected from the group consisting of (i) H, (ii) CN, (iii) NO 2 , (iv) halogen, (v) CN, halogen and OH.
- R 7 R 8 N— wherein R 7 and R 8 are the same or different and are substituted by a group selected from the group consisting of (1) H, (2) aryl and R 9 —O—CO—
- R 10 -T 1- where R 10 : (1) H, (2) aryl, HO—C 1-10 alkylene-O—, and lower alkyl optionally substituted by a group selected from the group consisting of HO, or (3) aryl, here T 1 : O or S
- R 11 -T 2- where R 11 : (1) OH, (2) R 7 R 8 N-, (3) lower alkyl-O
- R 1 and R 2 are the same or different and are (i) H or (ii) lower alkyl optionally substituted by one optionally substituted heterocyclic group;
- R 3 , R 4 , R 5 and R 6 are the same or different and are (i) H, (ii) halogen, or (iii) lower alkyl-O—.
- R 1 and R 2 Pyrimidines which are the same or different and may be substituted with a group selected from the group consisting of (i) H or (ii) halogen, lower alkyl and lower alkyl-O— And a pharmaceutical composition according to (1) or (2), which is lower alkyl optionally substituted with one heterocyclic group selected from pyridine.
- R 1 H
- R 2 lower alkyl substituted by one heterocyclic group selected from pyrimidine and pyridine, optionally substituted by a group selected from the group consisting of halogen, lower alkyl and lower alkyl-O—
- R 3 and R 6 H
- R 4 and R 5 The pharmaceutical composition according to (3), which is the same or different and is (i) H, (ii) halogen, or (iii) lower alkyl-O—.
- R 1 H
- R 2 lower alkyl substituted with pyrimidine optionally substituted by a group selected from the group consisting of halogen, lower alkyl and lower alkyl-O—
- R 3 and R 6 H
- R 4 and R 5 The pharmaceutical composition according to (4), which is the same or different and is (i) H, (ii) halogen, or (iii) lower alkyl-O—.
- R 1 H
- R 2 lower alkyl substituted with pyridine optionally substituted by a group selected from the group consisting of halogen, lower alkyl and lower alkyl-O—
- R 3 and R 6 H
- R 4 and R 5 The pharmaceutical composition according to (4), which is the same or different and is (i) H, (ii) halogen, or (iii) lower alkyl-O—.
- Specific compounds of the formula (I) included in the present invention include the following compounds. N- (4-Fluorophenyl) -N'-phenyl-N ''-(pyrimidin-2-ylmethyl) -1,3,5-triazine-2,4,6-triamine, N, N'-bis (4 -Fluorophenyl) -N "-(pyrimidin-2-ylmethyl) -1,3,5-triazine-2,4,6-triamine, N- (4-fluorophenyl) -N '-(4-methoxyphenyl) -N ''-(pyrimidin-2-ylmethyl) -1,3,5-triazine-2,4,6-triamine, N, N'-bis (4-fluorophenyl) -N ''-(pyrimidine-4 -Ylmethyl)-1,3,5-triazine-2,4,6-triamine, or N- (4-fluorophenyl) -N '-
- tautomers and geometric isomers may exist depending on the type of substituent.
- the compound of the formula (I) may be described in only one form of an isomer, but the present invention also includes other isomers, separated isomers, or those And mixtures thereof.
- the compound of formula (I) may have an asymmetric carbon atom or axial asymmetry, and optical isomers based on this may exist.
- the present invention also includes separated optical isomers of the compound of formula (I) or a mixture thereof.
- the present invention includes a pharmaceutically acceptable prodrug of the compound represented by the formula (I).
- a pharmaceutically acceptable prodrug is a compound having a group that can be converted to an amino group, a hydroxyl group, a carboxyl group, etc. (of the present invention) by solvolysis or under physiological conditions.
- groups that form prodrugs include those described in Prog. Med., 5, 2157-2161 (1985) and “Development of pharmaceuticals” (Yodogawa Shoten, 1990), Volume 7, Molecular Design 163-198. Is mentioned.
- the compound of formula (I) may form an acid addition salt or a salt with a base depending on the type of substituent, and is included in the present invention as long as such a salt is a pharmaceutically acceptable salt.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid Acid addition with organic acids such as lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyl tartaric acid, ditoluoyl tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid Salts, salts with inorganic bases such as sodium, potassium
- the compound of the formula (I) and / or a pharmaceutically acceptable salt thereof can be obtained by the production method described in US Pat. No. 7,375,222 or a production method according to them.
- a pharmaceutical composition containing one or more of the compounds of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is a pharmaceutical excipient or drug that is usually used in the art. It can be prepared by a commonly used method using a carrier or the like. Administration is orally by tablets, pills, capsules, granules, powders, solutions, etc., or injections such as intra-articular, intravenous, intramuscular, suppositories, eye drops, ophthalmic ointments, transdermal solutions, Any form of parenteral administration such as an ointment, a transdermal patch, a transmucosal liquid, a transmucosal patch, and an inhalant may be used.
- a solid composition for oral administration tablets, powders, granules and the like are used.
- one or more active ingredients are combined with at least one inert excipient such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone. And / or mixed with magnesium aluminate metasilicate.
- the composition may contain an inert additive, for example, a lubricant such as magnesium stearate, a disintegrant such as sodium carboxymethyl starch, a stabilizer, or a solubilizing agent according to a conventional method. .
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs and the like, and commonly used inert diluents such as purified water. Or ethanol.
- the liquid composition may contain solubilizers, wetting agents, auxiliaries such as suspending agents, sweeteners, flavors, fragrances, and preservatives.
- the injection for parenteral administration contains a sterile aqueous or non-aqueous solution, suspension or emulsion.
- aqueous solvent include distilled water for injection or physiological saline.
- non-aqueous solvents include propylene glycol, polyethylene glycol or vegetable oil such as olive oil, alcohols such as ethanol, or polysorbate 80 (a pharmacopeia name).
- Such compositions may further contain isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, or solubilizing agents. These are sterilized by, for example, filtration through a bacteria-retaining filter, blending with a bactericide or irradiation. These can also be used by producing a sterile solid composition and dissolving or suspending it in sterile water or a sterile solvent for injection before use.
- External preparations include ointments, plasters, creams, jellies, poultices, sprays, lotions, eye drops, eye ointments and the like.
- ointment bases include commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like.
- ointments or lotion bases include polyethylene glycol, propylene glycol, white petrolatum, white beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, etc. Can be mentioned.
- a transmucosal agent such as an inhalant or a nasal agent is used in a solid, liquid, or semi-solid state, and can be produced according to a conventionally known method.
- known excipients, and further pH adjusters, preservatives, surfactants, lubricants, stabilizers, thickeners and the like may be appropriately added.
- an appropriate device for inhalation or insufflation can be used.
- a known device such as a metered dose inhalation device or a nebulizer
- the compound is administered alone or as a powder in a formulated mixture or as a solution or suspension in combination with a pharmaceutically acceptable carrier. be able to.
- the dry powder inhaler or the like may be for single or multiple administration, and a dry powder or a powder-containing capsule can be used. Alternatively, it may be in the form of a pressurized aerosol spray using a suitable propellant, for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane or carbon dioxide.
- a suitable propellant for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane or carbon dioxide.
- the appropriate daily dose is about 0.001 to 100 mg / kg, preferably 0.1 to 30 mg / kg, more preferably 0.1 to 10 mg / kg per body weight. Or in 2 to 4 divided doses.
- the daily dose is suitably about 0.0001 to 10 mg / kg per body weight, and is administered once to several times a day.
- a transmucosal agent about 0.001 to 100 mg / kg per body weight is administered once to several times a day.
- the dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
- the compound of the formula (I) can be used in combination with a therapeutic or prophylactic agent for attention deficit / hyperactivity disorder.
- the combination may be administered simultaneously, separately separately, or at desired time intervals.
- the simultaneous administration preparation may be a compounding agent or may be separately formulated.
- REx Reference Example number
- mp melting point
- DATA physicochemical data
- FAB + FAB-MS ( M + H) +
- EI EI-MS (M) +
- NMR-DMSOd6 1 in DMSO-d 6 H NMR peak ⁇ (ppm)
- DMSO dimethyl sulfoxide
- THF tetrahydrofuran
- 4M hydrogen chloride / dioxane solution 4 mol / L hydrogen chloride dioxane solution
- MeCN acetonitrile
- MeOH methanol
- EtOH ethanol
- an aqueous solution prepared by adding 1.1 g of potassium carbonate to 308 mL of water was added for liquid separation, and the aqueous layer was separated.
- the organic layer was separated by adding 150 mL of water, the aqueous layer was separated, and the organic layer was concentrated under reduced pressure until the remaining amount of the solution was 280 mL.
- the operation of adding 750 mL of MeCN to the concentrated liquid and concentrating it under reduced pressure until the remaining amount of the solution was 280 mL was performed three times. Subsequently, 600 mL of MeCN was added and cooled, and then 34.43 g of aniline and 75 mL of MeCN were added at ⁇ 5.9 ° C.
- Tables 1 and 2 below show the structures and physical property values of Reference Example compounds.
- Example 1 Method for measuring BEC1 inhibitory activity of compounds using 86Rb ion release as an index
- the channel activity of BEC1 was measured using the release of radioisotope 86Rb ions from BEC1-expressing cells as an index according to the method described in US Pat. No. 6,326,168. That is, the radioactivity released from BEC1-expressing cells incorporating 86Rb ions with 100 mM KCl was defined as the channel activity of BEC1.
- 86Rb ions were incorporated into cells by culturing BEC1 stably expressing cells in the presence of 86RbCl (0.5 ⁇ Ci / ml) (3 hours, 37 ° C.), and 3 times with HEPES buffered saline (pH 7.4, 2.5 mM KCl). The 86Rb ions that were not incorporated were removed by washing twice. The cells are incubated with DMSO solution containing the test compound and HEPES buffered saline for 15 minutes at room temperature, and then further incubated with 100 mM KCl-containing HEPES buffer (pH 7.4) containing the same compound for 5 minutes at room temperature. Incubated with.
- the Cerenkov radioactivity of the extracellular fluid and the cell lysate was measured, and the total was taken as the total radioactivity.
- 86Rb ion release was expressed as a percentage of extracellular fluid radioactivity relative to total radioactivity.
- the value obtained in the presence of the compound was the test value, the value obtained in the absence of the compound was the control value, and the value obtained when not stimulated with 100 mM KCl was the blank value.
- the inhibitory action of the compound was expressed as an IC 50 value obtained from% inhibition (that is, (control value ⁇ test value) ⁇ 100 / (control value ⁇ blank value)).
- BEC1-expressing cells BEC1 stably expressing cells prepared according to the method described in US Pat. No. 6,326,168 using a dihydrofolate reductase (dhfr) deficient strain of Chinese hamster ovary cells were used. (result) Table 3 shows the test results of representative compounds. The compound was confirmed to have a BEC1 potassium channel inhibitory action.
- dhfr dihydrofolate reductase
- Example 2 Verification of the therapeutic effect on attention deficit / hyperactivity disorder was performed using stroke-prone spontaneously hypertensive rats (SHRSP).
- SHRSP stroke-prone spontaneously hypertensive rats
- This animal has the same characteristics as patients with attention deficit / hyperactivity disorder such as abnormalities in dopamine uptake protein, and also exhibits hyperactivity, attention deficit, impulsivity in early life, and attention deficit / hyperactivity It has been reported that it can be a model animal for sexual disorders (Ueno, K. et al., Behav. Pharmacol., 13: 1-13, 2003). Partially modified the method of Fox et al. (Fox, GB et al., Behav. Brain.
- the rats were placed in the light room of the passive avoidance reaction measuring apparatus, and the time until entering the dark room (entry latency) was measured up to 180 seconds.
- a very weak current was applied from the foot grit in the dark room. This trial was repeated 5 times, and the total of the entry latencies from the second time to the fifth time (cumulative approach latencies) was used as an index of the therapeutic effect on attention deficit / hyperactivity disorder.
- the significant difference test was performed between the solvent administration group and the drug administration group using Dunnett's test.
- the present invention is useful as an excellent pharmaceutical composition for preventing and / or treating attention deficit / hyperactivity disorder, which contains a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof. It is particularly useful as a pharmaceutical composition for the prevention and / or treatment of attention deficit / hyperactivity disorder carelessness, hyperactivity, impulsivity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明の他の目的は、BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩を有効成分として含有する注意欠陥/多動性障害予防剤及び/又は治療剤を提供することである。
本発明のさらなる目的は、注意欠陥/多動性障害予防及び/又は治療のためのBEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩を提供することである。
本発明のさらなる目的は、注意欠陥/多動性障害を治療するための医薬を製造するためのBEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩の使用を提供することである。
本発明のさらなる目的は、BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩の有効量を患者に投与することからなる注意欠陥/多動性障害を治療する方法を提供することである。
本発明のさらなる目的は、BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩、及び、製薬学的に許容される賦形剤を混合することからなる注意欠陥/多動性障害を治療するための医薬用組成物の製造方法を提供することである。
本発明のさらなる目的は、BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩を有効成分として含有する医薬組成物及びBEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩が注意欠陥/多動性障害を治療するために使用され得るまたは使用されるべき旨の記載を含むコマーシャルパッケージを提供することである。
A群
-OH、-NH2, -NH(低級アルキル)、-N(低級アルキル)2、-CN、-COOH、NO2、低級アルキル、低級アルキル-O-、ハロゲン、シクロアルキル、アリール、及び、ヘテロ環基。
ここで、上記A群に記載されるシクロアルキル、アリール、及び、ヘテロ環基は、下記のB群から選択される置換基によって置換されていてもよい。
B群
-OH、-NH2 、-NH(低級アルキル)、-N(低級アルキル)2、-CN、-COOH、NO2、低級アルキル、低級アルキル-O-、ハロゲン、シクロアルキル、アリール、及び、ヘテロ環基。
(1)BEC1カリウムチャネル阻害剤が、式(I)
R1及びR2:同一又は異なって、(i) H、(ii)OH、(iii)アルキル-O-、(iv)アリール-CO-、 (v)H2N、(vi)(OHで置換されていてもよいアルキル)-NH、 (vii)(アルキル)2N、(viii)置換されていてもよい炭化水素基、又は、(ix)置換されていてもよいヘテロ環基;
R3、R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)CN、 (iii)NO2、 (iv)ハロゲン、 (v)CN、ハロゲン及びOHからなる群から選択される基により置換されていてもよい低級アルキル、 (vi)シクロアルキル、 (vii)低級アルキルで置換されていてもよいアリール、(viii) 低級アルキルで置換されていてもよいヘテロ環基、 (ix)R7R8N-(ここでR7及びR8:同一又は異なって、 (1)H、(2)アリール及びR9-O-CO-からなる群から選択される基により置換されていてもよい低級アルキル(ここで、R9:(1)H、若しくは、(2)アリールで置換されていてもよい低級アルキル))、 (x)R10-T1-(ここでR10:(1)H、(2)アリール、HO-C1-10アルキレン-O-、及び、HOからなる群から選択される基によって置換されていてもよい低級アルキル、若しくは(3)アリール、 ここでT1:O若しくはS)、 又は(xi)R11-T2-(ここでR11:(1)OH、(2)R7R8N-、(3)低級アルキル-O-、(4)低級アルキル、(5)アリール、若しくは(6)ヘテロ環基、ここでT2:CO若しくはSO2)。)
の化合物である、注意欠陥/多動性障害予防用及び/又は治療用の医薬組成物。
R3、 R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)ハロゲン、又は、(iii) 低級アルキル-O-である(1)に記載の医薬組成物。
R2: ハロゲン、低級アルキル及び低級アルキル-O-からなる群から選択される基によって置換されていてもよい、ピリミジン及びピリジンから選択される1個のヘテロ環基、により置換された低級アルキル;
R3及びR6:H;
R4及びR5:同一又は異なって、 (i)H、 (ii)ハロゲン、 又は、(iii) 低級アルキル-O-である(3)に記載の医薬組成物。
(5)R1:H;
R2: ハロゲン、低級アルキル及び低級アルキル-O-からなる群から選択される基によって置換されていてもよいピリミジンにより置換された低級アルキル;
R3及びR6 :H;
R4及びR5:同一又は異なって、 (i)H、 (ii)ハロゲン、 又は、(iii) 低級アルキル-O-である(4)に記載の医薬組成物。
(6)R1:H;
R2: ハロゲン、低級アルキル及び低級アルキル-O-からなる群から選択される基によって置換されていてもよいピリジンにより置換された低級アルキル;
R3及びR6:H;
R4及びR5:同一又は異なって、 (i)H、 (ii)ハロゲン、 又は、(iii) 低級アルキル-O-である(4)に記載の医薬組成物。
(7)注意欠陥/多動性障害が、注意欠陥/多動性障害における不注意、衝動性、多動性である(1)乃至(6)に記載の医薬組成物。
N-(4-フルオロフェニル)- N'-フェニル-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミン、N,N'-ビス(4-フルオロフェニル)-N"-(ピリミジン-2-イルメチル)-1,3,5-トリアジン-2,4,6-トリアミン 、N-(4-フルオロフェニル)-N'-(4-メトキシフェニル)-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミン、N, N'-ビス(4-フルオロフェニル)-N''- (ピリミジン-4-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミン、又は、N-(4-フルオロフェニル)- N'-[(2-フルオロ-4-ピリジル)メチル] -N''-フェニル- 1,3,5-トリアジン-2,4,6-トリアミン。
また、式(I)の化合物には、不斉炭素原子や軸不斉を有する場合があり、これに基づく光学異性体が存在しうる。本発明は、式(I)の化合物の光学異性体の分離されたもの、あるいはそれらの混合物も包含する。
投与は錠剤、丸剤、カプセル剤、顆粒剤、散剤、液剤等による経口投与、又は、関節内、静脈内、筋肉内等の注射剤、坐剤、点眼剤、眼軟膏、経皮用液剤、軟膏剤、経皮用貼付剤、経粘膜液剤、経粘膜貼付剤、吸入剤等による非経口投与のいずれの形態であってもよい。
経口投与のための液体組成物は、薬剤的に許容される乳濁剤、溶液剤、懸濁剤、シロップ剤又はエリキシル剤等を含み、一般的に用いられる不活性な希釈剤、例えば精製水又はエタノールを含む。当該液体組成物は不活性な希釈剤以外に可溶化剤、湿潤剤、懸濁剤のような補助剤、甘味剤、風味剤、芳香剤、防腐剤を含有していてもよい。
REx:参考例番号、mp:融点、DATA:物理化学的データ(FAB+:FAB-MS(M+H)+、EI:EI-MS(M)+、NMR-DMSOd6:DMSO-d6中の1H NMRにおけるピークのδ(ppm))、DMSO:ジメチルスルホキシド、THF:テトラヒドロフラン、4M 塩化水素/ジオキサン溶液:4mol / L 塩化水素ジオキサン溶液、MeCN:アセトニトリル、MeOH:メタノール、EtOH:エタノール。
2Lフラスコにシアヌル酸クロリド75.0g、THF680mLを加え、攪拌しながら-19℃にて炭酸カリウム51.10gを加えた。-12.4℃以下にてp-フルオロアニリン41.08gをTHF75mLに溶解した溶液、及び、THF75mLを加えた。-12.8~-14.4℃にて1時間反応を行い、水450mLを加えた。室温にて分液を行い、水層を分離後に水300mLを加え再度分液を行い水層を分離した。有機層にTHF600mLを加えた後、炭酸カリウム1.1gを水308mLに加えて調製した水溶液を加えて分液を行い、水層を分離した。有機層に水150mLを加えて分液を行い、水層を分離し、有機層を溶液残量280mLになるまで減圧にて濃縮した。濃縮液にMeCN750mLを加えて減圧にて溶液残量280mLになるまで濃縮する操作を3回行った。続いてMeCN600mLを加えて冷却後、アニリン34.43g、MeCN75mLを-5.9℃以下で加え、N,N-ジイソプロピルエチルアミン47.79g、MeCN38mLを-9.2℃にて加えた。その後室温まで昇温し,12時間攪拌後に2-アミノメチルピリミジン48.42g、MeCN75mLを室温にて加えた後、N,N-ジイソプロピルエチルアミン57.35g、MeCN38mLを室温にて加えた。内温82.4℃に昇温し4.5時間撹拌後、内温70℃以上で水560mLを加えた後冷却した。内温65.8℃にて結晶析出を確認後、室温にて終夜放置し濾過を行った。得られた結晶をMeCN:水=2:1の混合溶液にて洗浄し、続いて水300mLで洗浄した。得られた結晶を50℃にて1日減圧乾燥を行い、108.54gのN-(4-フルオロフェニル)- N'-フェニル-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミンを得た。
メチルエチルケトン414L、N-(4-フルオロフェニル)- N'-フェニル-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミンの結晶23.00kgを反応容器1へ加え、内温65.0℃にて溶解させた。濾過を行い、反応容器2へ移送後、メチルエチルケトン23Lにて洗いこみを行い再度加熱した。別に、反応容器1にフマル酸6.90kg、EtOH 115Lを加え内温58.3℃にて溶解させ、反応容器2へと移送後、EtOH 23Lにて洗いこみを行った。冷却を開始し、内温54.2℃にて結晶析出を確認後、0℃にて終夜攪拌した。結晶を濾取しEtOH 46Lにて結晶を洗浄後、得られた「N-(4-フルオロフェニル)- N'-フェニル-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミンとフマル酸の比が1:1の塩の結晶」 30.34kg(湿重量)とEtOH 460Lを反応容器2に加えた。内温52.4~69.2℃にて懸濁状態で42時間攪拌し、冷却し室温にて終夜攪拌した。結晶を濾取しEtOH 46Lで結晶を洗浄後、60℃にて4日間減圧乾燥を行い「N-(4-フルオロフェニル)- N'-フェニル-N''- (ピリミジン-2-イルメチル)- 1,3,5-トリアジン-2,4,6-トリアミンとフマル酸の比が2:1の塩の無水物の結晶」20.97kgを得た。
2-ピリミジンカルボニトリル 25g の酢酸 100mL 及び酢酸エチル 100mL の混合溶液に、10% パラジウム/炭素 1g を加えて常圧の水素雰囲気下、室温で14時間攪拌した。反応混合物からパラジウム/炭素をセライト濾過により除去し、溶媒を留去して得られた残渣にトルエンを加えて濃縮する操作を4回行った。得られた残渣にMeCNを加えて固体化させて、固体を濾取して1-ピリミジン-2-イルメチルアミン酢酸塩 15.7g を無色固体として得た。
NMR-DMSOd6: 1.88 (3H, s), 3.91 (2H, brs), 4.1-5.3 (3H, m), 7.38 (1H, t, J=4.9Hz), 8.78 (2H, d, J=4.9Hz)
EI: 109
6-クロロ-N,N'-ビス(4-フルオロフェニル)-1,3,5-トリアジン-2,4-ジアミン 4.71g のMeCN 50mL 溶液に、1-ピリミジン-2-イルメチルアミン酢酸塩 2.507g 及び N,N-ジイソプロピルエチルアミン 5.2mL を加えて、75℃で17時間攪拌した。反応液を室温まで冷却した後、溶媒を留去して得られた残渣に酢酸エチルを加えて、有機層を5%クエン酸水溶液及び飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、溶媒を留去した。得られた残渣をシリカゲルカラムクロマトグラフィー(クロロホルム:MeOH=100:0~95:5)で精製して 6.0g の微黄色アモルファスを得た。このものをEtOH 180mL に溶解し、活性炭2gを加えて1時間攪拌した。活性炭をセライト濾過により除去し、溶媒を留去して得られた残渣を含水EtOH (EtOH 80%) 150mL から固体化させ、N,N'-ビス(4-フルオロフェニル)-N"-(ピリミジン-2-イルメチル)-1,3,5-トリアジン-2,4,6-トリアミン 4.84g を無色固体として得た。
得られたN,N'-ビス(4-フルオロフェニル)-N"-(ピリミジン-2-イルメチル)-1,3,5-トリアジン-2,4,6-トリアミン 1.5g をMeOH 300mL に溶解し、4M 塩化水素/ジオキサン溶液 2mL を加えた後、溶媒を留去して、得られた残渣をエタノールから結晶化させて「N,N'-ビス(4-フルオロフェニル)-N"-(ピリミジン-2-イルメチル)-1,3,5-トリアジン-2,4,6-トリアミンと塩化水素の比が1:2の塩」 1.66g を無色結晶として得た。
(試験法)
86Rbイオン放出量を指標とした化合物のBEC1阻害活性測定法
BEC1のチャネル活性は、米国特許第6326168号記載の方法に準じ、BEC1発現細胞からの放射性同位元素86Rbイオンの放出を指標として測定した。すなわち、86Rbイオンを取り込ませたBEC1発現細胞を100 mM KClで刺激した際に同細胞から放出される放射活性をBEC1のチャネル活性とした。86Rbイオンは、BEC1安定発現細胞を86RbCl(0.5μCi/ml)存在下で培養(3時間,37℃)することにより細胞に取り込ませ、HEPES緩衝生理食塩水(pH 7.4,2.5 mM KCl)で3回洗浄することにより取り込まれなかった86Rbイオンを取り除いた。同細胞は、被検化合物を含むDMSO溶液とHEPES緩衝生理食塩水を加えて15分間室温下でインキュベートし、その後同化合物を含む100 mM KCl含有HEPES緩衝液(pH 7.4)でさらに5分間室温下でインキュベートした。細胞外液を回収した後、残った細胞を0.1 N NaOHで溶解し回収した。
細胞外液と細胞溶解液のチェレンコフ放射活性をそれぞれ測定し、その合計を総放射活性とした。86Rbイオン放出量は、総放射活性に対する細胞外液放射活性の百分率で表した。化合物存在下で得られた値を検査値、化合物非存在下で得られた値をコントロール値、100 mM KClで刺激しなかった際に得られた値をブランク値とした。化合物の阻害作用は、阻害%(すなわち、(コントロール値-検査値)×100/(コントロール値-ブランク値))から求めたIC50値で表した。なお、BEC1発現細胞は、チャイニーズ・ハムスター卵巣細胞のジヒドロ葉酸レダクターゼ(dhfr)欠損株を用いて米国特許第6326168号記載の方法に準じて作成したBEC1安定発現細胞を用いた。
(結果)
代表的な化合物の試験結果を表3に示す。当該化合物はBEC1カリウムチャネル阻害作用を有することが確認された。
(実験)
注意欠陥/多動性障害に対する治療効果の検証は、脳卒中易発症性高血圧自然発症ラット(SHRSP)を用いて行った。この動物はドパミン取り込みタンパクの異常等の注意欠陥/多動性障害の患者と同様の性質を持つほか、若齢期において、多動性、注意力障害、衝動性を示し、注意欠陥/多動性障害のモデル動物となりうることが報告されている(Ueno, K. et al., Behav. Pharmacol., 13: 1-13, 2003)。Foxらの方法(Fox, G. B. et al., Behav. Brain. Res., 131: 151-161, 2002)を一部改変し、注意欠陥/多動性障害に対する薬剤の作用をSHRSPを用いた受動的回避反応試験を用いて検証した。すなわち、溶媒(Vehicle)又は、メチルフェニデート、化合物(1)、化合物(2)、化合物(3)、化合物(4)、化合物(5)を溶媒で複数の濃度に希釈した希釈液を、各群のラットに投与した。メチルフェニデートは皮下投与、化合物(1)~(5)は経口投与した。溶媒は、メチルフェニデートには生理食塩液、化合物(1)~(5)には0.5%メチルセルロース水溶液を用いた。各薬剤の投与30分後に、ラットを受動的回避反応測定装置の明室に入れ、暗室に入るまでの時間(進入潜時)を、最長で180秒まで測定した。暗室に入った場合、暗室の足グリットから、非常に微弱の電流を流した。この試行を5回繰り返し、2回目から5回目までの進入潜時の総和(累積進入潜時)を注意欠陥/多動性障害に対する治療効果の指標とした。有意差検定は、Dunnett検定を用い、溶媒投与群と薬物投与群との間で行った。
SHRSPにおける5回試行受動的回避反応試験の結果を表3に示す。表中の数値は,各化合物投与群の最小有効用量(溶媒投与群の累積進入潜時に対して、薬剤投与群の累積進入潜時が有意に長かった最も小さい用量)を表す.メチルフェニデート、化合物(1)、化合物(2)、化合物(3)、化合物(4)、化合物(5)はいずれもSHRSPの累積進入潜時を延長した。すなわち、化合物(1)~(5)は、メチルフェニデートと同様に注意欠陥/多動性障害の症状を改善する作用があることが示された。
Claims (12)
- 1)BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩、及び、2)製薬学的に許容できる担体を含有する注意欠陥/多動性障害予防用及び/又は治療用医薬組成物。
- BEC1カリウムチャネル阻害剤が、以下の式(I)の化合物である、請求項1に記載の医薬組成物。
R1及びR2:同一又は異なって、(i) H、(ii)OH、(iii)アルキル-O-、(iv)アリール-CO-、 (v)H2N、(vi)(OHで置換されていてもよいアルキル)-NH、 (vii)(アルキル)2N、(viii)置換されていてもよい炭化水素基、又は、(ix)置換されていてもよいヘテロ環基;
R3、R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)CN、 (iii)NO2、 (iv)ハロゲン、 (v)CN、ハロゲン及びOHからなる群から選択される基により置換されていてもよい低級アルキル、 (vi)シクロアルキル、 (vii)低級アルキルで置換されていてもよいアリール、(viii) 低級アルキルで置換されていてもよいヘテロ環基、 (ix)R7R8N-(ここでR7及びR8:同一又は異なって、 (1)H、(2)アリール及びR9-O-CO-からなる群から選択される基により置換されていてもよい低級アルキル(ここでR9:(1)H、若しくは、(2)アリールで置換されていてもよい低級アルキル)、 (x)R10-T1-(ここでR10:(1)H、(2)アリール、HO-C1-10アルキレン-O-、及び、HOからなる群から選択される基によって置換されていてもよい低級アルキル、若しくは(3)アリール、 ここでT1:O若しくはS)、 又は(xi)R11-T2-(ここでR11:(1)OH、(2)R7R8N-、(3)低級アルキル-O-、(4)低級アルキル、(5)アリール、若しくは(6)ヘテロ環基、ここでT2:CO若しくはSO2)。) - 式(I)が、
R1及びR2 が同一又は異なって、(i)H又は(ii)置換されていてもよい1個のヘテロ環基により置換されていてもよい低級アルキル;
R3、 R4、 R5及びR6が同一又は異なって、(i)H、 (ii)ハロゲン、又は、(iii) 低級アルキル-O-である、請求項2に記載の医薬組成物。 - BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩を有効成分として含有する注意欠陥/多動性障害予防剤及び/又は治療剤。
- BEC1カリウムチャネル阻害剤が、以下の式(I)の化合物である、請求項4に記載の予防剤及び/又は治療剤。
R1及びR2:同一又は異なって、(i) H、(ii)OH、(iii)アルキル-O-、(iv)アリール-CO-、 (v)H2N、(vi)(OHで置換されていてもよいアルキル)-NH、 (vii)(アルキル)2N、(viii)置換されていてもよい炭化水素基、又は、(ix)置換されていてもよいヘテロ環基;
R3、R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)CN、 (iii)NO2、 (iv)ハロゲン、 (v)CN、ハロゲン及びOHからなる群から選択される基により置換されていてもよい低級アルキル、 (vi)シクロアルキル、 (vii)低級アルキルで置換されていてもよいアリール、(viii) 低級アルキルで置換されていてもよいヘテロ環基、 (ix)R7R8N-(ここでR7及びR8:同一又は異なって、 (1)H、(2)アリール及びR9-O-CO-からなる群から選択される基により置換されていてもよい低級アルキル(ここでR9:(1)H、若しくは、(2)アリールで置換されていてもよい低級アルキル)、 (x)R10-T1-(ここでR10:(1)H、(2)アリール、HO-C1-10アルキレン-O-、及び、HOからなる群から選択される基によって置換されていてもよい低級アルキル、若しくは(3)アリール、 ここでT1:O若しくはS)、 又は(xi)R11-T2-(ここでR11:(1)OH、(2)R7R8N-、(3)低級アルキル-O-、(4)低級アルキル、(5)アリール、若しくは(6)ヘテロ環基、ここでT2:CO若しくはSO2)。) - 式(I)が、
R1及びR2 が同一又は異なって、(i)H又は(ii)置換されていてもよい1個のヘテロ環基により置換されていてもよい低級アルキル;
R3、 R4、 R5及びR6が同一又は異なって、(i)H、 (ii)ハロゲン、又は、(iii) 低級アルキル-O-である、請求項5に記載の予防剤及び/又は治療剤。 - 注意欠陥/多動性障害予防及び/又は治療のためのBEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩。
- BEC1カリウムチャネル阻害剤が、以下の式(I)の化合物である、請求項7に記載の化合物又はその製薬学的に許容できる塩。
R1及びR2:同一又は異なって、(i) H、(ii)OH、(iii)アルキル-O-、(iv)アリール-CO-、 (v)H2N、(vi)(OHで置換されていてもよいアルキル)-NH、 (vii)(アルキル)2N、(viii)置換されていてもよい炭化水素基、又は、(ix)置換されていてもよいヘテロ環基;
R3、R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)CN、 (iii)NO2、 (iv)ハロゲン、 (v)CN、ハロゲン及びOHからなる群から選択される基により置換されていてもよい低級アルキル、 (vi)シクロアルキル、 (vii)低級アルキルで置換されていてもよいアリール、(viii) 低級アルキルで置換されていてもよいヘテロ環基、 (ix)R7R8N-(ここでR7及びR8:同一又は異なって、 (1)H、(2)アリール及びR9-O-CO-からなる群から選択される基により置換されていてもよい低級アルキル(ここでR9:(1)H、若しくは、(2)アリールで置換されていてもよい低級アルキル)、 (x)R10-T1-(ここでR10:(1)H、(2)アリール、HO-C1-10アルキレン-O-、及び、HOからなる群から選択される基によって置換されていてもよい低級アルキル、若しくは(3)アリール、 ここでT1:O若しくはS)、 又は(xi)R11-T2-(ここでR11:(1)OH、(2)R7R8N-、(3)低級アルキル-O-、(4)低級アルキル、(5)アリール、若しくは(6)ヘテロ環基、ここでT2:CO若しくはSO2)。) - 式(I)が、
R1及びR2 が同一又は異なって、(i)H又は(ii)置換されていてもよい1個のヘテロ環基により置換されていてもよい低級アルキル;
R3、 R4、 R5及びR6が同一又は異なって、(i)H、 (ii)ハロゲン、又は、(iii) 低級アルキル-O-である、請求項8に記載の化合物又はその製薬学的に許容できる塩。 - BEC1カリウムチャネル阻害剤又はその製薬学的に許容できる塩の有効量を患者に投与することからなる注意欠陥/多動性障害を治療する方法。
- BEC1カリウムチャネル阻害剤が、以下の式(I)の化合物である、請求項10に記載の方法。
R1及びR2:同一又は異なって、(i) H、(ii)OH、(iii)アルキル-O-、(iv)アリール-CO-、 (v)H2N、(vi)(OHで置換されていてもよいアルキル)-NH、 (vii)(アルキル)2N、(viii)置換されていてもよい炭化水素基、又は、(ix)置換されていてもよいヘテロ環基;
R3、R4、 R5及びR6:同一又は異なって、 (i)H、 (ii)CN、 (iii)NO2、 (iv)ハロゲン、 (v)CN、ハロゲン及びOHからなる群から選択される基により置換されていてもよい低級アルキル、 (vi)シクロアルキル、 (vii)低級アルキルで置換されていてもよいアリール、(viii) 低級アルキルで置換されていてもよいヘテロ環基、 (ix)R7R8N-(ここでR7及びR8:同一又は異なって、 (1)H、(2)アリール及びR9-O-CO-からなる群から選択される基により置換されていてもよい低級アルキル(ここでR9:(1)H、若しくは、(2)アリールで置換されていてもよい低級アルキル)、 (x)R10-T1-(ここでR10:(1)H、(2)アリール、HO-C1-10アルキレン-O-、及び、HOからなる群から選択される基によって置換されていてもよい低級アルキル、若しくは(3)アリール、 ここでT1:O若しくはS)、 又は(xi)R11-T2-(ここでR11:(1)OH、(2)R7R8N-、(3)低級アルキル-O-、(4)低級アルキル、(5)アリール、若しくは(6)ヘテロ環基、ここでT2:CO若しくはSO2)。) - 式(I)が、
R1及びR2 が同一又は異なって、(i)H又は(ii)置換されていてもよい1個のヘテロ環基により置換されていてもよい低級アルキル;
R3、 R4、 R5及びR6が同一又は異なって、(i)H、 (ii)ハロゲン、又は、(iii) 低級アルキル-O-である、請求項11に記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011012743A MX2011012743A (es) | 2009-05-29 | 2010-05-28 | Nueva composicion farmaceutica para la prevencion y/0 tratamiento del trastorno por deficit de atencion/hiperactividad. |
CN201080023199XA CN102448495A (zh) | 2009-05-29 | 2010-05-28 | 用于预防和/或治疗注意缺陷/多动障碍的新型医药组合物 |
US13/322,669 US20120088772A1 (en) | 2009-05-29 | 2010-05-28 | Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder |
CA2762528A CA2762528A1 (en) | 2009-05-29 | 2010-05-28 | Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder |
EP10780643A EP2436396A4 (en) | 2009-05-29 | 2010-05-28 | NOVEL PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY |
JP2011516069A JPWO2010137689A1 (ja) | 2009-05-29 | 2010-05-28 | 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 |
BRPI1014545A BRPI1014545A2 (pt) | 2009-05-29 | 2010-05-28 | composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009129780 | 2009-05-29 | ||
JP2009-129780 | 2009-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010137689A1 true WO2010137689A1 (ja) | 2010-12-02 |
Family
ID=43222794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/059085 WO2010137689A1 (ja) | 2009-05-29 | 2010-05-28 | 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120088772A1 (ja) |
EP (1) | EP2436396A4 (ja) |
JP (1) | JPWO2010137689A1 (ja) |
KR (1) | KR20120036813A (ja) |
CN (1) | CN102448495A (ja) |
BR (1) | BRPI1014545A2 (ja) |
CA (1) | CA2762528A1 (ja) |
MX (1) | MX2011012743A (ja) |
WO (1) | WO2010137689A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103351348A (zh) * | 2013-07-15 | 2013-10-16 | 黄河三角洲京博化工研究院有限公司 | 一种2-甲胺基嘧啶盐酸盐的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326168B1 (en) | 1998-01-23 | 2001-12-04 | Yamanouchi Pahrmaceutical Co., Ltd. | Brain specific potassium channel protein |
WO2003066099A1 (fr) * | 2002-02-05 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de 2,4,6-triamino-1,3,5-triazine |
JP2003527818A (ja) * | 1998-08-14 | 2003-09-24 | エラン ファーマシューティカルズ,インコーポレイテッド | 新規なeskカリウムチャンネルのポリペプチドおよびポリヌクレオチドの組成物 |
US7094948B2 (en) | 2001-11-14 | 2006-08-22 | Astellas Pharma, Inc. | Transgenic animals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
US6759427B2 (en) * | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
US20100256145A1 (en) * | 2007-08-01 | 2010-10-07 | H. Lundbeck A/S | Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
-
2010
- 2010-05-28 JP JP2011516069A patent/JPWO2010137689A1/ja not_active Withdrawn
- 2010-05-28 CA CA2762528A patent/CA2762528A1/en not_active Abandoned
- 2010-05-28 US US13/322,669 patent/US20120088772A1/en not_active Abandoned
- 2010-05-28 MX MX2011012743A patent/MX2011012743A/es not_active Application Discontinuation
- 2010-05-28 EP EP10780643A patent/EP2436396A4/en not_active Withdrawn
- 2010-05-28 KR KR1020117028480A patent/KR20120036813A/ko not_active Application Discontinuation
- 2010-05-28 WO PCT/JP2010/059085 patent/WO2010137689A1/ja active Application Filing
- 2010-05-28 BR BRPI1014545A patent/BRPI1014545A2/pt not_active IP Right Cessation
- 2010-05-28 CN CN201080023199XA patent/CN102448495A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326168B1 (en) | 1998-01-23 | 2001-12-04 | Yamanouchi Pahrmaceutical Co., Ltd. | Brain specific potassium channel protein |
JP2003527818A (ja) * | 1998-08-14 | 2003-09-24 | エラン ファーマシューティカルズ,インコーポレイテッド | 新規なeskカリウムチャンネルのポリペプチドおよびポリヌクレオチドの組成物 |
US7094948B2 (en) | 2001-11-14 | 2006-08-22 | Astellas Pharma, Inc. | Transgenic animals |
WO2003066099A1 (fr) * | 2002-02-05 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de 2,4,6-triamino-1,3,5-triazine |
US7375222B2 (en) | 2002-02-05 | 2008-05-20 | Astellas Pharma Inc. | 2,4,6-Triamino-1,3,5-triazine derivative |
Non-Patent Citations (15)
Title |
---|
"Diagnostic and Statistical Manual of Mental Disorders", 2000, AMERICAN PSYCHIATRIC ASSOCIATION |
"Drug Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198 |
"Ionic Channels of Excited Membranes", 1992, SINAUER ASSOCIATES |
BARKLEY, R. A.; FISCHER, M.; EDELBROCK, C. S.; SMALLISH, L., J. AM. ACAD. CHILD ADOLESC. PSYCHIATRY, vol. 29, 1990, pages 546 - 557 |
BARKLEY, R. A.; FISCHER, M.; SMALLISH, L.; FLETCHER, K., J, ABNORM. PSYCHOL. ILL, 2002, pages 279 - 89 |
CLARKE, S.; HEUSSLER, H.; KOHN, M. R., INTERN. MED. J., vol. 35, 2005, pages 721 - 725 |
FOX, G. B. ET AL., BEHAV. BRAIN. RES., vol. 131, 2002, pages 151 - 161 |
GWILT, M.; ARROWSMITH, J. E.; BLACKBURN, K. J.; BURGES, R. A.; CROSS, P. E.; DALRYMPLE, H. W.; HIGGINS, A. J., J. PHARMACOL. EXP. THER., vol. 256, 1991, pages 318 - 324 |
KUTCHER, S.; AMAN, M.; BROOKS, S.J.; BUITELAAR, J.; DAALEN, E.; FEGERT, J.; FINDLING, R.L.; FISMAN, S.; GREENHILL, L.L.; HUSS, M., EUR. NEUROPSYCHOPHARMACOL., vol. 14, 2004, pages 11 - 28 |
LEVITAN, I. B.; KACZMAREK, L. K.: "The neuron: Cell and Molecular Biology", 1991, OXFORD UNIVERSITY PRESS |
PROG. MED., vol. 5, 1985, pages 2157 - 2161 |
See also references of EP2436396A4 |
UENO, K. ET AL., BEHAV. PHARMACOL., vol. 13, no. 1-13, 2003 |
WEISS, M.; MURRAY, C., CAN. MED. ASSOC. J., vol. 168, 2003, pages 715 - 722 |
YAMAGUCHI, S.; ROGAWSKI, M. A., EPILEPSY RES., vol. 11, 1992, pages 9 - 16 |
Also Published As
Publication number | Publication date |
---|---|
CA2762528A1 (en) | 2010-12-02 |
EP2436396A1 (en) | 2012-04-04 |
KR20120036813A (ko) | 2012-04-18 |
CN102448495A (zh) | 2012-05-09 |
US20120088772A1 (en) | 2012-04-12 |
BRPI1014545A2 (pt) | 2016-04-05 |
MX2011012743A (es) | 2012-04-20 |
EP2436396A4 (en) | 2012-10-31 |
JPWO2010137689A1 (ja) | 2012-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111788182B (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
CN102731499A (zh) | 内酰胺化合物及其作为药物的应用 | |
EP3697781B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
KR101839716B1 (ko) | 오렉신 수용체 길항제로서의 (s)-(2-(6-클로로-7-메틸-1h-벤조[d]이미다졸-2-일)-2-메틸피롤리딘-1-일)(5-메톡시-2-(2h-1,2,3-트리아졸-2-일)페닐)메타논의 결정성 염 형태 | |
KR20200081424A (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
AU2018300980A1 (en) | Antagonists of the muscarinic acetylcholine receptor M4 | |
WO2010134533A1 (ja) | アミノシクロヘキシルアルキル基を有する2,4-ジアミノピリミジン化合物 | |
JP5673676B2 (ja) | イミダゾ[1,2−a]ピリジン誘導体 | |
WO2010137689A1 (ja) | 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物 | |
KR20240055743A (ko) | Mnk 억제제를 사용한 편두통 치료 방법 | |
JP2012521963A (ja) | 新規統合失調症治療用医薬組成物 | |
US20100256152A1 (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
WO2017210408A1 (en) | Animal and human anti-trypanosomonal and anti-leishmania agents | |
CA3151863C (en) | Compound as potassium channel regulator and preparation and use thereof | |
AU2009201338A1 (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
US10870633B2 (en) | Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity | |
BRPI0901286A2 (pt) | nova composição farmacêutica para o tratamento da esquizofrenia | |
EP4240352A1 (en) | T-type calcium channel modulators and methods of use thereof | |
WO2022038574A1 (en) | Compounds for prevention or treatment of neurodegenerative disorders | |
WO2024040155A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
KR20200052938A (ko) | 테트라히드로나프틸우레아 유도체의 결정 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080023199.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10780643 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011516069 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2762528 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13322669 Country of ref document: US Ref document number: 2010780643 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117028480 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4878/KOLNP/2011 Country of ref document: IN Ref document number: MX/A/2011/012743 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1014545 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1014545 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111125 |